With a New Name and CEO, Inspyr Now Seeks a Partner for Cash to Fund Trial
Xconomy Texas — San Antonio — Inspyr is a biotech in need of a turnaround. Chris Lowe, the CEO who was officially hired this month to replace co-founder Craig Dionne, is hoping a deal with another drug developer can help make a U-turn in the business.
The 12-year-old San Antonio-based company has results from a Phase 2 trial of its drug, mipsagargin or G-202, in liver cancer (hepatocellular carcinoma) and would like to see that drug tested in Phase 3. Inspyr also has an ongoing Phase 2 trial of G-202 in glioblastoma, but wants to increase the dosing regimen because Lowe believes it may better show the potential efficacy and safety of the drug.
The 12-year-old San Antonio-based company has results from a Phase 2 trial of its drug, mipsagargin or G-202, in liver cancer (hepatocellular carcinoma) and would like to see that drug tested in Phase 3. Inspyr also has an ongoing Phase 2 trial of G-202 in glioblastoma, but wants to increase the dosing regimen because Lowe believes it may better show the potential efficacy and safety of the drug.